Diagnosis & treatment of tuberculosis in HIV co-infected patients

Indian Journal of Medical Research

Volumn 134, Issue 12, 2011, Pages 850-865

  Padmapriyadarsini, C ^a   Narendran, G ^a   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

Co infection; Diagnosis; Drug resistance; HIV; IRIS; Treatment; Tuberculosis

Indexed keywords

ABACAVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STREPTOMYCIN; TENOFOVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VOLATILE ORGANIC COMPOUND; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; AMNESIA; ANTIBODY DETECTION; ARTHRALGIA; ARTHROPATHY; BACTERIAL GROWTH; BACTERIUM CULTURE; COORDINATION; CRITICAL ILLNESS; DEPRESSION; DEVICES; DIABETES MELLITUS; DISEASE ASSOCIATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG TREATMENT FAILURE; ELECTRONIC NOSE DEVICE; FLU LIKE SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPY; GYNECOMASTIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION CONTROL; INSULIN RESISTANCE; INTERFERON GAMMA RELEASE ASSAY; JAUNDICE; LACTIC ACIDOSIS; LINE PROBE ASSAY; LIPID BLOOD LEVEL; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MICROSCOPY; MIXED INFECTION; MULTIDRUG RESISTANCE; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NUCLEIC ACID AMPLIFICATION; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PSYCHOSIS; RASH; REVIEW; SIDE EFFECT; SPUTUM SMEAR; SPUTUM SMEAR MICROSCOPY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS; VERTIGO; VOMITING;

EID: 84856586829     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.92630     Document Type: Review

References (119)

1. Global Report. UNAIDS repot on the global AIDS epidemic 2010. Available from: http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf, accessed on September 20, 2011.
2. Corbett E, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21.
3. Lawn S, Churchyard G. Epidemiology of HIV associated tuberculosis. Curr Opin HIV AIDS 2009; 4: 325-33.
4. WHO report 2010. Global tuberculosis control. Available from: http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf, accessed on September 20, 2011.
5. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2007; 191: 150-8.
6. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300: 423-30.
7. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infectionassociated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010; 50: S201-7.
8. Towards universal access by 2010: How WHO is working with countries to scale-up HIV prevention, treatment, care and support. Geneva: WHO; 2007. Available from: https://www. who.int/hiv/mediacentre/universal_access_progress_report_en.pdf, accessed on 20 September 28, 2011.
9. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-12.
10. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol 2005; 5: 819-26.
11. Interim policy on collaborative TB/HIV activities. Geneva: World Health Organization; 2004 (Report no: WHO/HTM/TB/2004.330).
12. Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10: 523-9.
13. Mohammed A, Ehrlich R, Wood R, Cilliers F, Maartens G. Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. Int J Tuberc Lung Dis 2004; 8: 792-5.
14. Shah S, Demissie M, Lambert L, Ahmed J, Leulseged S, Kebede T, et al. Intensified tuberculosis case finding among HIV-infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr 2009; 50: 537-45.
15. WHO (2007) Improving the diagnosis and treatment of smearnegative pulmonary and extrapulmonary tuberculosis among adults and adolescents: Recommendations for HIV-prevalent and resource-constrained settings. Available from: http://whqlibdoc.who.int/hq/2007/WHO_HTM_TB_2007.379_eng. pdf, accessed on September 20, 2011.
16. Koole O, Thai S, Khun KE, Pe R, van Griensven J, Apers L, et al. Evaluation of the 2007 WHO guideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults. PLoS ONE 2011; 6 (4): e18502. doi:10.1371/journal. pone.0018502.
17. Getahun H, Kittikraisak W, Heiling CM, Corbett EL, Ayles H, Cain KP, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource constrained settings: Individual participant data meta-analysis of observational studies. PLoS Med 2011; 8 (1): e1000391.
18. Post FA, Wood R, Pillay GP. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+Tlymphocytes count. Tuberc Lung Dis 1995; 76: 518-21.
19. Swaminathan S, Narendran G, Menon PA, Padmapriyadarsini C, Arunkumar N, Sudharshanam NM, et al. Impact of HIV infection on radiographic features in patients with pulmonary tuberculosis. Indian J Chest Dis Allied Sci 2007; 49: 133-6.
20. Churchyard G, Fielding KL, Lewis JJ, Chihota VN, Hanifa Y, Grant AD. Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening. AIDS 2010; 24: S19-27 49.
21. Hopewell P, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006; 6: 710-25.
22. Cattamanchi A, Dowdy DW, Davis JL, Worodria W, Yoo S, Joloba M, et al. Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis 2009; 9: 53.
23. Elliot AM, Namaambo K, AllenBW, Luo N, Hayes RJ, Pobee JO, et al. Negative sputum smear results in HIV positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tubercle Lung Dis 1993; 74: 191-4.
24. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6: 570-81.
25. Cattamanchi A, Davis JL, Pai M, Huang L, Hopewell PC, Steingart KR, et al. Does bleach processing increase the accuracy of sputum smear microscopy for diagnosing pulmonary tuberculosis? J Clin Microbiol 2010; 48: 2433-9.
26. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6: 664-74.
27. Yassin MA, Cuevas LE. How many sputum smears are necessary for case finding in pulmonary tuberculosis? Trop Med Int Health 2003; 8: 927-32.
28. Dorman S. New diagnostic tests for tuberculosis: bench, bedside, and beyond. Clin Infect Dis 2010; 50 (Suppl 3): 173-7.
29. FIND study trials at a glance: Primo Star iLED microscope. Available from: http://www.finddiagnostics.org, accessed on September 10, 2011.
30. Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, Waddell R, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40: 1500-7.
31. World Health Organization. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings. Geneva: World Health Organization; 2007.
32. Williams-Bouyer N, Yorke R, Lee HI, Woods GL. Comparison of the BACTEC MGIT 960 and ESP culture system II for growth and detection of mycobacteria. J Clin Microbiol 2000; 38: 4167-70.
33. Gil-Setas A, Torroba L, Fernandez JL, Martinez-Artola V, Olite J. Evaluation of the MB/BacT system compared with Middlebrook 7H11 and Lowenstein-Jensen media for detection and recovery of mycobacteria from clinical specimens. Clin Microbiol Infect 2004; 10: 224-8.
34. Lee JJ, Suo J, Lin CB, Wang JD, Lin TY, Tsai YC. Comparative evaluation of the BACTEC MGIT 960 system with solid medium for isolation of mycobacteria. Int J Tuberc Lung Dis 2003; 7: 569-74.
35. Farnia P, Mohammadi F, Mirsaedi M, Zarife AZ, Tabatabee J, Bahadori K, et al. Application of oxidation reduction assay for monitoring treatment of patients with pulmonary tuberculosis. J Clin Microbiol 2004; 42: 3324-5.
36. Moore DA, Mendoza D, Gilman RH, Evans CA, Hollm Delgado MG, Guerra J, et al. Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug resistant tuberculosis suitable for use in resource poor settings. J Clin Microbiol 2004; 42: 4432-7.
37. Kalantri S, Pai M, Pascopella L, Riley L, Reingold A. Bacteriophage based tests for the detection of Mycobacterium tuberculosis in clinical specimens: a systematic review and meta-analysis. BMC Infect Dis 2005; 5: 59.
38. Pai M, Minion J, Steingart K, Ramsay A. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 2010; 16: 271-84.
39. Baylan O, Kisa O, Albay A, Doganci L. Evaluation of a new automated, rapid, colorimetric culture system using solid medium for laboratory diagnosis of tuberculosis and determination of anti-tuberculosis drug susceptibility. Int J Tuberc Lung Dis 2004; 8: 772-7.
40. Chaudahary M, Gupta S, Khare S, Lal S. Diagnosis of tuberculosis in an era of HIV pandemic: A review of current status and future prospects. Indian J Med Micro 2010; 28: 281-9.
41. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in mycobacterium tuberculosis: A systematic review and meta analysis. BMC Infect Dis 2005; 5: 62.
42. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug resistant tuberculosis. Available from: http://www.who.int/tb/laboratory/lpa_policy.pdf, accessed on September 15, 2011.
43. Chauhan L.S. Status Report on RNTCP. Indian J Tuberc 2009; 56: 151-3.
44. World Health Organization and STOP TB department. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Available from: http://www.who.int/tb/laboratory/roadmap_xpert_mtb-rif.pdf, accessed on October 5, 2011.
45. Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, Reither K et al. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay-a clinical validation study. PLoS One 2011; 6: e20458.
46. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn 2010; 10: 937-46.
47. Zeka AN, Tasbakan S, Cavusoglu C. Evaluation of the GeneXpert MTB/RIF Assay for the Rapid Diagnosis of Tuberculosis and detection of RIF-resistance in Pulmonary and Extra pulmonary Specimens. J Clin Microbiol 2011; 49: 4138-41.
48. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Eng J Med 2010; 363: 1005-15.
49. Gennaro ML. Immunologic diagnosis of tuberculosis. Clin Infect Dis 2000; 30: S243-6.
50. Chan ED, Heifets L, Iseman MD. Immunologic diagnosis of tuberculosis: A review. Tuberc Lung Dis 2000; 80: 131-40.
51. Wanchu A. Advances in serology for diagnosing TB in the HIV infected. Indian J Chet Dis Allied Sci 2005; 47: 31-7.
52. Morris K. WHO recommends against inaccurate tuberculosis tests. Lancet 2011; 377: 113-4.
53. Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis. PLoS Med 2011; 8: e1001074.
54. Khosla R, Dwivedi A, Sarin BC, Sehajpal PK. Peripheral blood based C-PCR assay for diagnosing extra-pulmonary tuberculosis. Indian J Exp Biol 2009; 47: 447-53.
55. Kashyap RS, Ramteke SS, Morey SH, Purohit HJ, Taori GM, Daginawala HF. Diagnostic value of early secreted antigenic target-6 for the diagnosis of tuberculous meningitis patients. Infection 2009; 37: 508-13.
56. Mutetwa R, Boehme C, Dimairo M, Bandason T, Munyati SS, Mangwanya D, et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis 2009; 13: 1253-9.
57. Shah M, Variava E, Holmes CB, Coppin A, Golub JE, McCallum J, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 2009; 52: 145-51.
58. Swaminathan S, Subbaraman R, Venkatesan P, Subramanyam S, Kumar SR, Mayer KH, et al. Tuberculin skin test results in HIV-infected patients in India: Implications for latent tuberculosis treatment. Int J Tuberc Lung Dis 2008; 12: 168-73.
59. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4: 761-76.
60. Liebeschuets S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with T-cell based assay: A prospective cohort study. Lancet 2004; 364: 2196-203.
61. Rangaka MX, Wilkinson KA, Seldone R, Van Cutsem G, Meintjes GA, Morroni C, et al. The effect of HIV-1 infection on T-cell based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175: 514-20.
62. Pai M. Alternatives to the tuberculin skin test: interferon γ assays in the diagnosis of Mycobacterium tuberculosis infection. Indian J Med Micro 2005; 23: 151-8.
63. World Health Organization. Strategic and Technical Advisory Group (STAG-TB). 2010. Report of the 10th Meeting. Available from: http://www.who.int/tb/advisory_bodies/stag_tb_report_2010.pdf, accessed on September 30, 2011.
64. Philips M, Basa-Dalay V, Bothamley G, Cataneo RN, Lam PK, Natividad MPR, et al. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis 2010; 90: 145-51.
65. Banday KM, Pasikanti KK, Chan EC, Singla R, Rao KV, Chauhan VS, et al. Use of urine volatile organic compounds to discriminate tuberculosis patients from healthy subjects. Anal Chem 2011; 83: 5526-34.
66. Arend Kolk, Michael Hoelscher, Leonard Maboko, Jung J, Kuijper S, Cauchi M, et al. Electronic-nose technology using sputum samples in diagnosis of patients with tuberculosis. J Clin Microbiol 2010; 48: 4235-8.
67. World Health Organization UNJPoHA. Guidance on provider initiated HIV testing and counseling in health facilities. Geneva: World Health Organization, 2007.
68. Vijay S, Swaminathan S, Vaidyanathan P, Thomas A, Chauhan LS, Kumar P, et al. Feasibility of Provider-Initiated HIV Testing and Counseling of tuberculosis patients under the TB Control Programme in two districts of South India. PLoS One 4(11): e7899.
69. World Health Organization. Essential Prevention and Care Interventions for adults and adolescents living with HIV in resource limited settings. Geneva: World Health Organization; 2008.
70. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomized placebo controlled trials. BMJ 1998; 317: 625-9.
71. Bucher H, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13: 501-7.
72. Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Stop TB department. World Health Organization, Geneva 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241500708_eng. pdf, accessed on August 2, 2011.
73. Churchyard GJ, Scano F, Geant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007; 196: S52-62.
74. Swaminathan S, Menon PA, Narendran G, Venkatesan P, Ramesh Kumar S, Ranjani Ramachandran, et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: A Randomized clinical trial. Unpublished Data.
75. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365: 11-20.
76. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomized, double-blind, placebo-controlled trial. Lancet 2011: 377: 1588-98.
77. NACO Annual Report 2010-2011. Available from: http://www. nacoonline.org/upload/REPORTS/NACO%20Annual%20 Report%202010-11.pdf, accessed on September 30, 2011.
78. Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare. TB India 2008-RNTCP status report. Available from; http://www.tbcindia. org/pdfs/TB-India-2008.pdf, accessed on October 2, 2011.
79. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomized trial. Lancet 2004; 364: 1244-51.
80. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effect of human immunodeficiency virus infection on recurrences of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37: 101-12.
81. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181: 743-51.
82. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, et al. Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-6.
83. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175: 1199-206.
84. WHO Library Cataloguing-in-Publication Data: Treatment of tuberculosis: guidelines, 4th ed., accessed on September 28, 2011 from WHO/HTM/TB/2009.420.
85. Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection on the recurrence of Tuberculosis in South India. J Infect Dis 2010; 201: 691-703.
86. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, et al. Efficacy and safety of once-daily nevirapine-or efavirenz-based antiretroviral therapy in HIV associated tuberculosis: A randomized clinical trial. Clin Infect Dis 2011; 53: 716-24.
87. Khan FA, 87. Minion J, Pai M, Royce S, Burman W, Harries AD, et al. Treatment of active tuberculosis in HIV-coinfected patients: A systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-99.
88. Swaminathan S, Padmapriyadarsini C, Ponnuraja C, Ranjani R, Sriram S, Kumar RS, et al. Tuberculosis treatment outcomes among patients treated with a short-course intermittent anti-TB regimen and either once-daily Nevirapine or Efavirenz based antiretroviral therapy: a randomized clinical trial. Abstract presented in 41st Union World Conference on Lung Health, Berlin, November 2011. 2010; Clinical trials. gov number NCT00332306.
89. Antiretroviral therapy for HIV infection in adults and adolescents-World Health organization 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf, accessed on September 12, 2011.
90. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents Including Post-exposure Prophylaxis-National Aids Control organization 2007. Available from: http://upaidscontrol.up.nic.in/ART%20Guidelines%20 for%20HIV-Infected%20Adults%20and%20Adolescents%20 Including%20Post-exposure.pdf, accessed on September 12, 2011.
91. de Jong BC, Israelski DM, Corbett EL, Small PM. Clinical management of tuberculosis in the context of HIV infection. Annu Rev Med 2004; 55: 283-301.
92. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196: S63-S75.
93. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005; 19: 148 1486.
94. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received Rifampicin. HIV Med 2008; 9: 294-9.
95. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without Rifampicin. Clin Infect Dis 2006; 43: 253-5.
96. Blanc F, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365: 1471-81.
97. Havlir D, Ive P, Kendall M, Luetkemeyer A, Swindells S, Kumwenda J, et al. A5521 Team International Randomized Trial of Immediate vs Early ART in HIV+ Patients Treated for TB: ACTG 5221 STRIDE Study. Abstract presented at the XVIII Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27-Mar 2; Boston (MA).
98. Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 25: 697-70.
99. Torok ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52: 1374-83.
100. World Health Organization. An evaluation of the impact of early initiation of Highly Active Anti-Retroviral Therapy (HAART) on Tuberculosis (TB) treatment outcomes for TB patients co-infected with Human Immunodeficiency Virus (HIV) [ISRCTN77861053]. Current Controlled Trials [online]. Available from: http://www.controlledtrials.com, accessed on October 9, 2011.
101. Shao HJ, Crump JA, Ramadhani HO, Uiso LO, Ole-Nguyaine S, Moon AM, et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses 2009; 25: 1277-85.
102. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. International network for the study of HIV-associated IRIS. Tuberculosis associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-23.
103. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIVinfected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-73.
104. Robertson JC, Fichtenbaum CJ. Case on the Web: diagnosis and management of the immune reconstitution syndrome in HIV-infected patients. International AIDS Society-USA Web site. Available from: http://www.iasusa.org/cow. Presentation 37, accessed on September 30, 2011.
105. Kumar RS, Narendran G, Patrawalla P, Menon PA, Mayer K, Swaminathan S. Immune reconstitution inflammatory syndrome in HIV infected patients with and without prior tuberculosis. Unpublished data.
106. Lawn SD, Myer L, Beckker LG, Wood R. Tuberculosis associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-73.
107. Ratnam I, Chiu C, Kandal NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42: 418-27.
108. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-61.
109. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39: 1709-12.
110. Breen RA, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, et al Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59: 704-7.
111. M, Wall J, Ying J, Fitctenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42: 1639-46.
112. Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007; 46: 456-62.
113. Price P, Morahan G, Huang D, Stone E, Cheong KY, Castley A, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002; 16: 2043-7.
114. Bourgarit A, Carcelain G, Martinez V, Lascoux C, Delcey V, Gicquel B, et al. Explosion of tuberculin specificTh1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20: F1-F7.
115. Swaminathan S, Paramasivan CN, Ponnuraja C, Iliayas S, Rajasekaran S, Narayanan PR. Anti-tuberculosis drug resistance tuberculosis in South India. Int J Tuberc Lung Dis 2005; 9: 896-900.
116. Pereira M, Tripathy S, Inamdar V, Ramesh K, Bhavsar M, Date A, et al. Drug resistance pattern of Mycobacterium tuberculosis in seropositive and seronegative HIV-TB patients in Pune, India. Indian Med J Res 2005; 121: 235-9.
117. Wells CD, Cegielski P, Nelson LJ, Laserson KF, Holtz TH, Finlay A, et al. HIV infection and multidrug resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196: S86-S107.
118. Revised National Tuberculosis Control Programme-DOTS plus guidelines 2010. Available from: http://www.tbcindia. org/pdfs/DOTS_Plus_Guidelines_Jan2010.pdf, accessed on October 13, 2011.
119. Thomas BE, Ramachandran R, Anitha S, Swaminathan S. Feasibility of routine HIV testing among TB patients through a Voluntary, Counseling and Testing Centre (VCTC). Int J Tuberc Lung Dis 2007; 11: 1296-301.